AssureMDx is a multi-omics, liquid biopsy urine test designed to triage patients with hematuria who are at risk for bladder cancer and to monitor for recurrence in post-treatment patients. It is offered as a laboratory-developed test (LDT) performed in the company's CLIA-certified, CAP-accredited laboratory.

• ·Integrates DNA methylation and somatic mutation biomarkers for a comprehensive analysis
• ·Achieves 96% overall sensitivity and a 99% Negative Predictive Value (NPV)
• ·Demonstrates 95.9% sensitivity for detecting early Stage 0/I bladder cancer
• ·Recognized in AUA guidelines for evaluating intermediate-risk microscopic hematuria